Insmed/INSM

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Ticker

INSM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Bridgewater, United States

Employees

912

Insmed Metrics

BasicAdvanced
$10B
Market cap
-
P/E ratio
-$5.21
EPS
0.93
Beta
-
Dividend rate
$10B
0.93
1.803
1.504
-244.44
-294.245
-8.67%
-31.79%
293.21%
29.33
-20.64
-15.19
-15.72
22.54%
21.42%
23.43%
18.08%

What the Analysts think about Insmed

Analyst Ratings

Majority rating from 17 analysts.
Buy

Insmed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-207.94% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$76M
-9.69%
Net income
-$157M
-15.59%
Profit margin
-207.94%
-6.54%

Insmed Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.89%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.78
-$1.11
-$1.28
-$1.06
-
Expected
-$1.13
-$1.13
-$1.15
-$1.23
-$1.13
Surprise
57.40%
-1.94%
11.68%
-13.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insmed stock?

Insmed (INSM) has a market cap of $10B as of July 03, 2024.

What is the P/E ratio for Insmed stock?

The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of July 03, 2024.

Does Insmed stock pay dividends?

No, Insmed (INSM) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next Insmed dividend payment date?

Insmed (INSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Insmed?

Insmed (INSM) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Insmed stock

Buy or sell Insmed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing